Clinical Trials
3
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
The TRICURE EU Pivotal Study
- Conditions
- Tricuspid Valve RegurgitationHeart Valve DiseaseCardiovascular Diseases
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- TRiCares
- Target Recruit Count
- 80
- Registration Number
- NCT06581471
- Locations
- 🇧🇪
Algemeen Stedelijk Ziekenhuis, Aalst, Belgium
🇧🇪ZNA Middelheim, Antwerpen, Belgium
🇧🇪UZ Brussel, Bruxelles, Belgium
The TRICURE EFS Study
- Conditions
- Tricuspid Valve RegurgitationHeart Valve DiseasesCardiovascular Diseases
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- TRiCares
- Target Recruit Count
- 10
- Registration Number
- NCT06506942
- Locations
- 🇺🇸
Piedmont Healthcare Inc., Atlanta, Georgia, United States
🇺🇸Northwestern, Chicago, Illinois, United States
🇺🇸University of Michigan Hospital and Health Systems, Ann Arbor, Michigan, United States
The TRICURE First in Human Trial
- Conditions
- Tricuspid Regurgitation
- First Posted Date
- 2021-11-18
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- TRiCares
- Target Recruit Count
- 20
- Registration Number
- NCT05126030
- Locations
- 🇧🇪
Algemeen Stedelijk Ziekenhuis,, Aalst, Belgium
🇧🇪ZNA Middelheim, Antwerpen, Belgium
🇧🇪Cliniques Universitaires Saint-Luc UCL, Bruxelles, Belgium
News
TRiCares Announces First U.S. Implantations of Topaz TTVR System in Early Feasibility Study
TRiCares has successfully implanted its Topaz transcatheter tricuspid heart valve replacement (TTVR) system in the first patients in a U.S. Early Feasibility Study.